Free Daily Podcast Summary
The MedTech Podcast: Daily Summaries Delivered
by Karandeep Singh Badwal
The MedTech Podcast shares the journey behind the path of the people shaping the MedTech industry and its future. Join me as I connect with industry leaders, thought providers and innovators.Hosted by Karandeep Singh Badwal, Karandeep is a Quality & Regulatory Consultant specialising in the MedTech Industry. If you have any ideas for future episodes or would like to be on the podcast then feel free to connect with me via the links belowFollow Karandeep on LinkedIn: https://www.linkedin.com/in/karandeepbadwal/Follow Karandeep on YouTube: https://www.youtube.com/c/KarandeepBadwal/
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago23 min
#108 The Trillion Dollar Admin Problem with Dan: Putting Patients at the Centre of US Healthcare, the Letter That Changed Everything and Why Timing Beats Ideas
Dan, founder of Patient.com and a healthcare technology entrepreneur with over 30 years in the industry and five companies behind him, including Search America, now used in around 3,500 hospitals across the US.In this episode, Dan takes us back to where it all started. A telecoms job with a debt collection trade association revealed that most of that industry’s revenue came from healthcare, and the reason was simple: data in healthcare does not flow the way it does everywhere else. That insight pulled him into revenue cycle software and set the course for his entire career.The turning point came from a letter. A cancer patient wrote to thank Search America after a hospital clerk told her she qualified for full financial assistance, something she never knew. She had waited a year before going in, by which point her cancer had progressed. That moment convinced Dan the software belonged in the hands of patients, not just hospital staff, and it became the seed for Patient.com.We get into how Patient.com works, why consent and trust had to be built in from day one, how AI is used to translate what Dan calls healthcare speak into plain language and where the line sits between an admin platform and a regulated product. Dan also explains why his first attempt ten years ago failed because consumers simply were not ready, how Patient.com plugs into the existing plumbing of healthcare rather than replacing it and why roughly a trillion dollars of US healthcare spend is lost to administrative waste that rarely makes the news.Timestamps[00:02:00] Why She Gave Up a Faculty Position Most Scientists Chase[00:03:32] Learning to Be a Founder Before Making the Leap[00:05:38] Epitranscriptomics Explained in Plain Terms[00:09:07] The Prodromal Phase and Detecting MS Before Symptoms[00:11:31] Why Reimbursement Is Built for Reactive Medicine[00:13:45] What Most People Do Not Understand About Living With MS[00:15:20] Could This Replace the Spinal Tap and Repeat MRIs?[00:17:39] The Operational Chaos Nobody Warns First-Time Founders About[00:19:48] Why So Many Life Science Investors Will Not Touch Diagnostics[00:22:30] Why Nobody Has Done This Before: Sample Access as a MoatConnect with Dan - https://www.linkedin.com/in/daniel-johnson-ceoLearn more about Patient.com - https://patient.comGet in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
- Sep 29, 202626 min
#107 Catching Disease Five Years Early with Caroline Vissers: Walking Away From Faculty, Why Investors Avoid Diagnostics and Rethinking When We Diagnose
Caroline Vissers, co-founder of Immunectra and a former UCSF faculty member, who walked away from a lab of her own to build a company. Working alongside scientific co-founders Joe DeRisi and Michael Wilson, Caroline is developing blood-based tests capable of detecting autoimmune disease long before a patient ever shows symptoms.In this episode, Caroline shares why she gave up a faculty position most scientists spend a career chasing, how she prepared for the jump with a venture capital course and consulting work before committing and why the entrepreneurial path was always the real destination. She also breaks down epitranscriptomics in plain terms and explains the unusual path that led from RNA methylation research into autoimmunity.The core of the conversation is early detection. Caroline explains the prodromal phase, why MS patients often wait years for a diagnosis while irreversible neurological damage is already happening and what it means to detect disease up to five years before onset. We get into the uncomfortable reality that healthcare reimbursement is built for reactive medicine rather than prediction, how employer-based insurance may open the door and why she is upfront that policy will have to catch up with the science.We also cover the access to biobanked military samples that made the discovery possible and now serves as a competitive moat, why so many life science investors avoid diagnostics entirely and Caroline's advice for anyone weighing up a leap into founding a company.Timestamps[00:02:00] Why She Gave Up a Faculty Position Most Scientists Chase[00:03:32] Learning to Be a Founder Before Making the Leap[00:05:38] Epitranscriptomics Explained in Plain Terms[00:09:07] The Prodromal Phase and Detecting MS Before Symptoms[00:11:31] Why Reimbursement Is Built for Reactive Medicine[00:13:45] What Most People Do Not Understand About Living With MS[00:15:20] Could This Replace the Spinal Tap and Repeat MRIs?[00:17:39] The Operational Chaos Nobody Warns First-Time Founders About[00:19:48] Why So Many Life Science Investors Will Not Touch Diagnostics[00:22:30] Why Nobody Has Done This Before: Sample Access as a MoatConnect with Sandy - https://www.linkedin.com/in/caroline-vissers-b7431285/Learn more about Immunecetra - https://qb3.org/invoke-bio-immunectra-win-100k-qb3-mentoring-awards-for-precision-cancer-vaccines-ms-diagnostic/https://qb3.org/im-all-in-immunectras-founder-left-her-faculty-position-to-form-groundbreaking-company/Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
- Aug 31, 202625 min
#106 What Notified Bodies Actually Look For with Sandy Wright: Why SaMD Submissions Fail, the EU AI Act and Getting to Market Faster
Sandy Wright, Head of Devices at Scarlet, the first notified body built specifically around software as a medical device. A former doctor who moved from clinical practice into digital health. Sandy now sits on the assessment side of the table, reviewing the very submissions most manufacturers dread putting together.In this episode, we start with the question that trips up so many companies. What actually turns a piece of software into a medical device and why is the wellness boundary still so blurry that entire businesses are straddling the divide without realising it. Sandy shares some of the more unusual examples out there, including AI ambient scribes and augmented reality tools that let surgeons revisit patient scans mid-operation.We then go inside Scarlet itself. Sandy explains why they see themselves as a technology company first and a notified body second, how a combination of expertise, redesigned process and their own internal tooling means customers are not sitting at the back of a queue for months and what genuinely drives faster conformity assessment.The most valuable part for anyone in this space is Sandy's breakdown of where nonconformities actually come from. Clinical evaluation, post-market clinical follow up treated as an afterthought, incomplete software requirements and risk analyses that are too narrow. We also cover the EU AI Act and how it may or may not intersect with MDR, what makes a genuinely good PCCP and Sandy's parting advice on the underrated power of narrative in a regulatory submission.Timestamps[00:01:00] What Actually Turns Software Into a Medical Device[00:03:39] AI Scribes and AR Headsets: SaMD You Might Not Expect[00:06:10] Why Scarlet Sees Itself as a Technology Company First[00:08:43] How Scarlet Cut Assessment Timelines Without Cutting Corners[00:12:12] Clinical Evaluation: The Most Common Source of Findings[00:13:18] Why Post-Market Clinical Follow Up Is Treated as an Afterthought[00:16:20] Risk Management and Why a Narrow Lens Causes Problems[00:16:55] The EU AI Act and How It May Intersect With MDR[00:19:56] From Foundation Doctor to Babylon Health and Beyond[00:22:42] What Separates a Good PCCP From a Box-Ticking OneConnect with Sandy - https://www.linkedin.com/in/wrightsandy/Learn more about Scarlet - https://www.scarlet.cc/Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
- Aug 17, 202627 min
#105 Inside the Transplant Industry with Tom Daulton: The Device Keeping Donated Organs Alive, Why the US Dominates Transplants and Building in a Niche Market
Tom Daulton, CEO of Organ Recovery Systems, who has spent over 40 years in interventional medicine and building healthcare companies. Twelve months ago he knew very little about the transplant world. Today he runs one of the most fascinating businesses in it.In this episode, Tom explains what makes transplant unlike anything else in medicine, a field where sadly a patient has to die for another to live and where there is no pharmaceutical fallback the way dialysis can bridge a failing kidney. He breaks down why over 80% of transplants happen in the US, why the real bottleneck is donor supply rather than surgical capacity and how organs actually move across the country against a ticking clock.We get into the technology at the heart of the business, the egg-shaped hypothermic perfusion device roughly the size of a carry-on that keeps a donated organ stable and monitored for over 24 hours, GPS telemetry and all, a world away from the cardboard box of ice that used to be standard. Tom walks us through what an organ procurement facility looks like from the inside, why each organ needs its own dedicated device and what is coming next after kidney and liver.Finally, Tom shares hard-won advice for anyone building in a small niche market with real emotional weight, why you have to hire the experts, why falling in love with your product is a trap and why every niche business has to prove it is safer, faster, cheaper or better for outcomes. He closes on the tagline he lives by: be hungry and humble.Timestamps[00:01:35] From 40 Years in Interventional Medicine to the Transplant World[00:03:53] The Business Where a Patient Has to Die for Another to Live[00:05:11] Why Over 80% of Transplants Happen in the US[00:07:38] Not Enough Facilities or Not Enough Donors?[00:09:16] Inside the Egg: What the Perfusion Device Actually Does[00:13:28] How Organs Were Moved Before: A Cardboard Box of Ice[00:15:10] How Much Time the Machine Really Buys[00:17:20] Inside an Organ Procurement Facility[00:22:04] Why Every Organ Needs Its Own Device[00:29:11] Final Advice: Be Hungry and HumbleConnect with Tom - https://www.linkedin.com/in/tom-daulton-7230367/Learn more about Organ Recovery Systems - https://www.organ-recovery.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
- Aug 3, 202624 min
#104 From Investor to Inventor with Joanna Nathan: Rethinking Early Stage Lung Cancer Surgery, Raising Capital and the Changing Face of the Disease
Joanna Nathan, CEO and co-founder of Prana Surgical, adjunct professor at Rice University and a former MedTech investor who spent years at the J&J MedTech Center for Device Innovation before crossing over into building herself. Her company recently secured FDA clearance for the Prana System, a tissue-sparing platform rethinking how early stage lung cancer is diagnosed and treated.In this episode, Joanna shares the deeply personal story behind her move from investing back into operating, having lost her four year old son in 2021 and wanting proximity to patient impact rather than evaluating innovation from the sidelines. It is an honest and moving conversation about what actually drives someone to take on a decade-long mission.We get into what she learned watching hundreds of pitches from the investor seat, why a no is very often about portfolio construction and timing rather than the quality of your idea, and why a fundraising pitch is a vision document backed by evidence rather than a journal article. Joanna then breaks down the problem Prana is solving, why removing large portions of lung for a tiny early stage nodule is no longer justifiable and how the system is right-sized for the level of risk these smaller lesions present.We also explore the changing face of lung cancer, the rise of never smokers now approaching one in three patients, why the disease is getting younger and more female, the role of mobile screening in rural areas and where AI genuinely helps rather than replaces clinical judgement. Joanna closes with hard-won advice for anyone thinking about founding a company and why community is what carries you through.Timestamps[00:01:38] From Research to Investing to Building: The Path Back to Operating[00:03:33] Why a No From an Investor Is Rarely About Your Idea[00:05:29] Why a Pitch Is a Vision Document Not a Journal Article[00:07:16] The Problem With Early Stage Lung Cancer Surgery Today[00:09:22] The Rise of Never Smokers and a Disease That Is Changing Fast[00:11:03] Why Women Under 50 Now Face Higher Lung Cancer Rates[00:13:18] Getting Creative on Access: Mobile CT Screening in Rural Areas[00:17:21] AI in MedTech: Assisting Clinical Judgement Not Replacing It[00:19:22] How Houston Became an Unlikely MedTech Powerhouse[00:24:06] Who Should Not Become a Founder and the Decade-Long QuestionConnect with Joanna - linkedin.com/in/joannacnathan/Learn more about Prana Surgical - https://www.pranasurgical.com/Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
- Jul 20, 202626 min
#103 Why Faster Is Not Always Better with Basant Bajpai: EU MDR vs FDA, the GCC Regulatory Landscape and Where Innovators Get Stuck
Dr. Basant Bajpai CEO of Compliance MedQRA, a UAE-based consulting company specializing in Quality Assurance, Regulatory Affairs, AI governance and compliance for medical devices, SaMD, AI/ML health technologies and digital health solutions. He holds a PhD in Neuroscience focused on brain monitoring and neurotechnology and has more than 12 years of international experience supporting MedTech and digital health companies across Europe, the Middle East and the United States.He explains why regulatory and quality is still one of the most misunderstood functions in MedTech and why so many innovators treat it as a documentation exercise until it becomes an expensive problem at the worst possible moment. We get into the question every founder asks, how long will this take and what will it cost and why there is genuinely no straight answer without first building a proper regulatory strategy.We also tackle the growing trend of companies choosing the US over EU MDR simply because it looks faster. Basant makes the case that regulatory approval alone does not guarantee commercial entry, why reimbursement codes should shape your market choice more than approval timelines and why he now finds EU MDR more convenient than many people expect. He also shares a contrarian view on device classification and why staying in the lowest risk class is not always the smart play.Finally, we explore the GCC regulatory landscape, which Basant argues is not less regulated but differently regulated, with data compliance requirements he found tougher than GDPR or HIPAA. He closes with a clear message on AI in healthcare and why he does not believe regulators will ever allow a clinician to be replaced.Timestamps[00:01:23] From Biomedical Engineering to a First Audit That Changed Everything[00:03:33] Why Everyone Thinks Regulatory Is Just a Documentation Department[00:06:07] How Long Will It Take and What Will It Cost: The Impossible Question[00:09:35] EU MDR vs FDA: Why Reimbursement Should Drive the Decision[00:12:19] Regulatory Approval Does Not Guarantee Commercial Success[00:14:36] Why Staying in the Lowest Risk Class Can Backfire[00:16:00] The GCC: Not Less Regulated, Just Differently Regulated[00:18:24] Why Data Compliance in the Gulf Is Tougher Than GDPR[00:23:30] Who Should Not Pursue a Career in Quality and Regulatory[00:29:17] Final Advice: AI Will Transform Healthcare but Not Replace CliniciansConnect with Basant - https://www.linkedin.com/in/basant-bajpai-phd-63565961Learn more about Complaince MedQRA - https://www.compliancemedqra.net/Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
- Jun 1, 202625 min
#102 The End of the Amyloid Era with Isaac Stoner: Treating Alzheimer's as a Disease of the Immune System
Isaac Stoner, CEO of MindImmune Therapeutics, a drug discovery company pioneering a new class of medicines for Alzheimer's disease and other neurodegenerative conditions.Isaac has built his career moving between the founder seat and the investor seat. He was the founding CEO of Octagon Therapeutics, the first team member at liquid biopsy company Firefly BioWorks and has evaluated life science companies for investment at Slater Technology Fund, PureTech Health, KdT and Action Potential Venture Capital. At MindImmune Therapeutics, he is chasing one of the boldest ideas in neuroscience: that Alzheimer's may in fact be an autoimmune disease that presents in the brain.In this episode Isaac explains why the amyloid hypothesis that has dominated Alzheimer's research for 30 years has run its course, and why MindImmune is taking an immunology-first approach built on brain tissue donated by Alzheimer's patients. He breaks down the three biggest risk factors for the disease, how he pitched a 30 million dollar Series A on a condition where 99.9% of drugs have failed and what it would mean to develop a therapy bigger than the GLP-1 weight loss drugs.We also get into the founder-to-investor-to-founder journey, why a brilliant scientific founder is often the wrong person to sit in the CEO seat and the hard truths every aspiring biotech founder needs to hear before striking out on their own.Timestamps[00:02:50] Why a Career Investor Keeps Getting Pulled Back Into Building[00:05:25] Shutting Down Octagon Therapeutics and the Chip It Left Behind[00:07:10] Why MindImmune Treats Alzheimer's as an Autoimmune Disease[00:08:20] Why 30 Years of the Amyloid Hypothesis Has Run Its Course[00:10:05] The Three Biggest Risk Factors for Alzheimer's and What You Can Do[00:12:15] How He Raised a $30 Million Series A on the Hardest Disease in Medicine[00:15:30] Why 99.9% of Alzheimer's Drugs Fail and What Makes This Different[00:18:35] Why a Brilliant Scientific Founder Is Often the Wrong CEO[00:22:20] Where MindImmune Goes Next: AMD, ALS and Beyond[00:28:00] Final Advice: Get Into Biotech for the Right ReasonsConnect with Isaac - https://www.linkedin.com/in/isaacstoner/Learn more about MindImmune Therapeutics - https://www.mindimmune.com/Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
- May 4, 202624 min
#101 When Great Technology Is Not Enough with Shai Policker: Why most MedTech Startups Still Fail, Venture Studios vs VC and the Israeli Edge
Shai Policker, Co-Founder and Managing Partner at Edge Medical Ventures, a medtech venture studio and fund focused on developing and investing in medical devices that address unmet clinical needs. With a BSc in Electrical Engineering from the Technion, an MBA from Columbia Business School and over 25 years building medical device companies, Shai has founded or scaled 18 companies across cardiovascular care, surgery and respiratory health, filing more than 40 patents along the way.In this episode, Shai cuts straight to something most investors won't say out loud: that even a great technology with strong clinical data can still fail. Not because the product is wrong but because the process takes too long and the funding runs out. He breaks down the fragmented decision-making landscape in healthcare, why physicians loving your product means almost nothing if the payer isn't on board and why reimbursement is the real gatekeeper that kills more companies than bad science ever will.We also explore what makes Edge Medical Ventures different from a traditional VC fund. Shai explains how their venture studio model starts from validated unmet needs with a strategic partner already at the table and how their hands-on go-to-market support continues well past the R&D phase. A combination that helped one portfolio company go from zero to FDA approval with distribution agreements and paying customers on just $2.5 million. We also get into the Israeli startup mindset, the right way to think about IP and patents and how to know when a founder should step aside.Timestamps[00:00:17] What Pulled an Electrical Engineer Into MedTech 25 Years Ago[00:01:48] What 18 Companies Taught Shai That One Never Could[00:03:04] How to Know If the Problem Is Painful Enough to Build Around[00:04:56] Why 80% of MedTech Startups Fail Even With Great Technology[00:07:53] What a Venture Studio Actually Is and How It Differs From a VC Fund[00:10:51] The $2.5 Million Company That Got FDA Approval and Started Selling[00:13:54] Why Israeli Startups Move Faster Than Everyone Else[00:17:28] How to Think About Patents Without Becoming Obsessed With Them[00:23:44] Balancing Speed and Discipline Without Creating Expensive Mistakes[00:26:20] Final Advice: What Shai Wishes Every MedTech Founder KnewConnect with Shai - https://www.linkedin.com/in/shai-policker-b8760a3/Learn more about Edge Medical Ventures - https://edgemed.vc/Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalMedical device training courses delivered by Karandeep through Bywater - https://www.bywater.co.uk/
Get The MedTech Podcast summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
TED Tech
Experts examine how technology reshapes society, science, design, and business through TED Talks hosted by Sherrell Dorsey.
Get Better Faster
Doctors and researchers discuss functional medicine and root-cause approaches to chronic illness and health optimization.
Extend Podcast with Darshan Shah, MD
Explores science-backed strategies and expert insights to extend healthspan and optimize longevity through actionable health protocols.
King Dems Podcast | Growth Mindset, Leadership, AI and Business Insights
Discusses leadership, AI, and business growth with CEOs and entrepreneurs through practical insights on strategy, innovation, and mindset.
DGTL Voices with Ed Marx
Conversations with leaders and innovators driving digital transformation in healthcare.
Thriving Minds with Alberto Zandi
Conversations with experts and high achievers explore practical insights for thriving in business, career, and personal growth.
The BioHub - by Avetix
Conversations with leading biotech experts reveal the strategies and stories driving innovation in the biotechnology industry.
Made for Health | Peptides | Lyme | Chronic Infections | Long Covid | Insulin Resistance | Hypermobility
A physician explores science-based approaches to treating chronic conditions and restoring health.
The Biohacking Standards
A deep dive into biohacking fundamentals—nutrition, movement, sleep, and mindfulness—grounded in science and holistic wellness principles.
Treated with Dr. Sara Szal
Dr. Sara Szal explores holistic health solutions through conversations with experts and patients seeking mind, body, and soul healing.
The VPZD Show
Two physicians discuss healthcare, medicine, and policy from a contrarian, middle-ground perspective.
Unriveted
Discusses technology, AI, machine learning, data engineering, cloud services, and the startup experience.
About The MedTech Podcast
The MedTech Podcast shares the journey behind the path of the people shaping the MedTech industry and its future. Join me as I connect with industry leaders, thought providers and innovators.Hosted by Karandeep Singh Badwal, Karandeep is a Quality & Regulatory Consultant specialising in the MedTech Industry. If you have any ideas for future episodes or would like to be on the podcast then feel free to connect with me via the links belowFollow Karandeep on LinkedIn: https://www.linkedin.com/in/karandeepbadwal/Follow Karandeep on YouTube: https://www.youtube.com/c/KarandeepBadwal/
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The MedTech Podcast in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The MedTech Podcast daily summary?
It's a free AI-powered email that summarizes new episodes of The MedTech Podcast as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The MedTech Podcast podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The MedTech Podcast product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Karandeep Singh Badwal.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
What topics does The MedTech Podcast cover?
The MedTech Podcast covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The MedTech Podcast summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.